KR102068010B1 - 염증성 피부 질환의 치료 - Google Patents

염증성 피부 질환의 치료 Download PDF

Info

Publication number
KR102068010B1
KR102068010B1 KR1020157002889A KR20157002889A KR102068010B1 KR 102068010 B1 KR102068010 B1 KR 102068010B1 KR 1020157002889 A KR1020157002889 A KR 1020157002889A KR 20157002889 A KR20157002889 A KR 20157002889A KR 102068010 B1 KR102068010 B1 KR 102068010B1
Authority
KR
South Korea
Prior art keywords
apc
psoriasis
skin
pharmaceutical composition
keratinocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157002889A
Other languages
English (en)
Korean (ko)
Other versions
KR20150036351A (ko
Inventor
크리스토퍼 존 잭슨
밀랑 슈에
Original Assignee
제트제트 바이오테크 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902874A external-priority patent/AU2012902874A0/en
Application filed by 제트제트 바이오테크 엘엘씨 filed Critical 제트제트 바이오테크 엘엘씨
Publication of KR20150036351A publication Critical patent/KR20150036351A/ko
Application granted granted Critical
Publication of KR102068010B1 publication Critical patent/KR102068010B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157002889A 2012-07-04 2013-07-04 염증성 피부 질환의 치료 Active KR102068010B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
AU2012902874 2012-07-04
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (2)

Publication Number Publication Date
KR20150036351A KR20150036351A (ko) 2015-04-07
KR102068010B1 true KR102068010B1 (ko) 2020-01-20

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157002889A Active KR102068010B1 (ko) 2012-07-04 2013-07-04 염증성 피부 질환의 치료

Country Status (12)

Country Link
US (3) US20150150954A1 (enExample)
EP (1) EP2869833B1 (enExample)
JP (1) JP6273272B2 (enExample)
KR (1) KR102068010B1 (enExample)
CN (1) CN104394883B (enExample)
AU (1) AU2013286812B2 (enExample)
BR (1) BR112015000051A2 (enExample)
CA (1) CA2877745C (enExample)
ES (1) ES2676422T3 (enExample)
IN (1) IN2014DN11181A (enExample)
RU (1) RU2662564C2 (enExample)
WO (1) WO2014005183A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN11181A (enExample) * 2012-07-04 2015-10-02 Univ Sydney
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
PL3137102T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
CA3124949A1 (en) * 2018-12-26 2020-07-02 Direct Biologics Llc Methods and compositions for treating skin and hair disorders
KR20210137026A (ko) 2019-02-07 2021-11-17 다이렉트 바이오로직스 엘엘씨 중간엽 줄기세포 엑소좀, 활액 중간엽 줄기세포 및 스캐폴드의 조합을 이용한 골관절염 치료 방법
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
EP3999083A4 (en) 2019-07-18 2023-07-26 Direct Biologics LLC Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US20230159932A1 (en) 2020-04-22 2023-05-25 Direct Biologics Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072328A2 (en) * 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
WO2002100445A1 (en) * 2001-06-13 2002-12-19 The University Of Sydney Treatment and composition for wound healing
JP2011524884A (ja) * 2008-06-20 2011-09-08 アンバート ミレー イグナシオ 皮膚炎疾患、たとえば、皮膚炎、アトピー性皮膚炎、白斑、円形脱毛症、アクネ、乾癬、そう痒またはその組合せのようなものの処置のための皮膚科の製薬上の組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
JPH03501921A (ja) 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
BR9809292A (pt) 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
CA2398929C (en) 2000-02-04 2011-05-31 The Scripps Research Institute Neuroprotective, antithrombotic and anti-flammatory uses of activated protein c (apc)
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
JP4071105B2 (ja) 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
AU2003275948A1 (en) * 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
DE50304744D1 (de) 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US7498305B2 (en) 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
US20100297099A1 (en) 2005-06-24 2010-11-25 Lars Otto Uttenthal Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
WO2010113146A1 (en) * 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
IN2014DN11181A (enExample) * 2012-07-04 2015-10-02 Univ Sydney
PL3137102T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
US20170035862A1 (en) * 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072328A2 (en) * 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
WO2002100445A1 (en) * 2001-06-13 2002-12-19 The University Of Sydney Treatment and composition for wound healing
JP2011524884A (ja) * 2008-06-20 2011-09-08 アンバート ミレー イグナシオ 皮膚炎疾患、たとえば、皮膚炎、アトピー性皮膚炎、白斑、円形脱毛症、アクネ、乾癬、そう痒またはその組合せのようなものの処置のための皮膚科の製薬上の組成物

Also Published As

Publication number Publication date
CN104394883A (zh) 2015-03-04
JP6273272B2 (ja) 2018-01-31
CN104394883B (zh) 2017-05-31
AU2013286812B2 (en) 2017-04-20
BR112015000051A2 (pt) 2017-06-27
AU2013286812A1 (en) 2015-01-22
US20170080062A1 (en) 2017-03-23
EP2869833B1 (en) 2018-04-04
EP2869833A1 (en) 2015-05-13
KR20150036351A (ko) 2015-04-07
RU2662564C2 (ru) 2018-07-26
IN2014DN11181A (enExample) 2015-10-02
WO2014005183A1 (en) 2014-01-09
CA2877745A1 (en) 2014-01-09
US11617785B2 (en) 2023-04-04
RU2015103510A (ru) 2016-08-27
HK1204573A1 (en) 2015-11-27
US20200276281A1 (en) 2020-09-03
US20150150954A1 (en) 2015-06-04
EP2869833A4 (en) 2015-11-18
JP2015521632A (ja) 2015-07-30
CA2877745C (en) 2021-11-30
ES2676422T3 (es) 2018-07-19

Similar Documents

Publication Publication Date Title
US11617785B2 (en) Treatment of inflammatory skin disorders
AU679165B2 (en) Treatment of inflammation
JP2006508971A (ja) プロテアーゼ阻害剤を使用して炎症性疾患を治療する組成物及び方法
TWI868051B (zh) 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
US5190917A (en) Treatment of psoriasis
KR102112883B1 (ko) 피부 염증 질환의 치료 방법
EP3137102B1 (en) Apc for use in the treatment of abnormal cutaneous scarring
WO2022002160A1 (zh) Pcsk9抑制剂在制备治疗多种疾病产品中的应用
US11311484B2 (en) Methods and compositions for treating skin afflictions
KR20010042402A (ko) 피부 상처의 치료를 위한 프로테아제 억제제의 용도
HK1204573B (en) Treatment of inflammatory skin disorders
JPH0565492B2 (enExample)
JP2002522396A (ja) 乾癬治療用プロテアーゼ阻害因子
DE69732784T2 (de) Inhibierung von invasiver remodulierung
CN115120730A (zh) Pcsk9抑制剂在制备预防和治疗疤痕产品中的应用
Cole Dermatologic Therapies
RU2855148C2 (ru) Средство с рекомбинатным аналогом пептида морской анемоны для лечения аллергического дерматита и псориаза
TWI740342B (zh) 胜肽ＣＰＰｅｃｐ二聚體用於治療皮膚炎之用途
Bubna et al. Brodalumab: Looking beyond psoriasis
Bubna Apremilast
Pranjali An Unusual Presentation of Lichen Planus
Sharma An Unusual Presentation of Lichen Planus
US20020155179A1 (en) Treatment of inflammatory diseases including psoriasis
ZHENG Overview of the drug therapy for Psoriasis
HK1235306B (zh) 治疗异常皮肤瘢痕形成

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6